A detailed history of Orbimed Advisors LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 1,297,800 shares of APLS stock, worth $49.8 Million. This represents 1.72% of its overall portfolio holdings.

Number of Shares
1,297,800
Previous 922,200 40.73%
Holding current value
$49.8 Million
Previous $55.2 Million 38.19%
% of portfolio
1.72%
Previous 1.35%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$55.39 - $72.47 $20.8 Million - $27.2 Million
375,600 Added 40.73%
1,297,800 $76.3 Million
Q4 2023

Feb 14, 2024

SELL
$37.14 - $64.82 $12.6 Million - $21.9 Million
-338,300 Reduced 26.84%
922,200 $55.2 Million
Q3 2023

Nov 14, 2023

BUY
$23.65 - $89.22 $8.28 Million - $31.3 Million
350,300 Added 38.49%
1,260,500 $47.9 Million
Q1 2023

May 15, 2023

BUY
$46.59 - $66.96 $42.4 Million - $60.9 Million
910,200 New
910,200 $60 Million
Q2 2020

Aug 14, 2020

SELL
$24.8 - $38.49 $1.25 Million - $1.94 Million
-50,485 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$17.91 - $44.33 $904,186 - $2.24 Million
50,485 New
50,485 $1.35 Million
Q4 2019

Feb 14, 2020

SELL
$22.1 - $30.8 $13.8 Million - $19.2 Million
-623,859 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$24.09 - $32.18 $28.9 Million - $38.6 Million
-1,199,841 Reduced 65.79%
623,859 $15 Million
Q2 2019

Aug 14, 2019

BUY
$18.0 - $25.34 $1.11 Million - $1.56 Million
61,400 Added 3.48%
1,823,700 $46.2 Million
Q1 2019

May 15, 2019

BUY
$12.81 - $19.82 $18.4 Million - $28.4 Million
1,435,300 Added 438.93%
1,762,300 $34.4 Million
Q4 2018

Feb 14, 2019

BUY
$11.47 - $18.71 $3.75 Million - $6.12 Million
327,000 New
327,000 $4.31 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $4.21B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Orbimed Advisors LLC Portfolio

Follow Orbimed Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.